EXMceuticals (EXM) is focused on the sustainable cultivation of cannabis and hemp, from which it will extract and sell pharmaceutical grade ingredients. It intends to be the largest volume, lowest cost producer and supplier of cannabis ingredients and cannabidiol (CBD) products to the pharmaceutical, nutraceutical, therapeutical & cosmetic markets.
EXM is headquartered in Canada, with its cultivation operations located in several countries in Central/Southern Africa - Uganda, Malawi & the Democratic Republic of the Congo (DRC). In Portugal, EXM has applied for a license to establish a research lab, a nursery and a center for processing & distribution, with the facility acting as a base for distribution in the EU and North America.
Central Africa provides an ideal location for cannabis cultivation, particularly given the favourable climate, quality of soil and availability of labour. In the DRC, EXM has been granted first right of refusal over concessions of over 100,000 acres, giving it the potential to create one of the largest cannabis ingredients production facilities in the world.
EXM’s target clients will be operators in the pharmaceutical, therapeutical, nutraceutical & cosmetic industries which require large volumes of high quality cannabis derived ingredients, primarily CBD & terpenes, for their products. EXM is looking to offer a secure ingredient supply chain & plans to enter into long-term off-take agreements, as well as explore opportunities to sell in the spot market. The recreational cannabis market will not be targeted.
Bank of America Merrill Lynch estimates that the total addressable global cannabis market (legal + illegal sales) is currently worth US$166 billion. This highlights the huge growth potential for industry participants as governments continue to legalise and regulate the market. In addition to this, it estimates that CBD in the three core markets of the US, Europe, and Canada, could represent roughly US$7 billion today, growing to nearly US$40 billion by 2032.
Our DCF valuation is $389.1 million, or $7.65 per share, almost 6 times the current share price. This assumes funding of $15 million in 2019. Being highly conservative in our assumptions, we see significant upside potential to our valuation. Accordingly, we initiate coverage of EXMceuticals with a stance of Conviction Buy.